BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23214487)

  • 1. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
    Karhanová M; Mlčák P; Fryšák Z; Marešová K
    Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
    Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
    Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
    Traverso CE; Ropo A; Papadia M; Uusitalo H
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
    Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
    Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spanish multicenter tafluprost tolerability study.
    Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
    Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
    Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
    Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C; Neville MW
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
    Lee W; Lee S; Bae H; Kim CY; Seong GJ
    BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
    Holló G; Katsanos A
    Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
    Kuwayama Y; Nomura A
    Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
    Konstas AG; Holló G
    Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.